MX359672B - Metodo para manejo de dolor cronico y tratamiento usando hcg. - Google Patents

Metodo para manejo de dolor cronico y tratamiento usando hcg.

Info

Publication number
MX359672B
MX359672B MX2013012078A MX2013012078A MX359672B MX 359672 B MX359672 B MX 359672B MX 2013012078 A MX2013012078 A MX 2013012078A MX 2013012078 A MX2013012078 A MX 2013012078A MX 359672 B MX359672 B MX 359672B
Authority
MX
Mexico
Prior art keywords
hcg
day
chronic pain
treatment
methods
Prior art date
Application number
MX2013012078A
Other languages
English (en)
Other versions
MX2013012078A (es
Inventor
Conrad Hicks Edson Jr
T Dutton Constance
Original Assignee
Neuralight Hd Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/211,101 external-priority patent/US8680086B2/en
Application filed by Neuralight Hd Llc filed Critical Neuralight Hd Llc
Publication of MX2013012078A publication Critical patent/MX2013012078A/es
Publication of MX359672B publication Critical patent/MX359672B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31545—Setting modes for dosing
    • A61M5/31548—Mechanically operated dose setting member
    • A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6063—Optical identification systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un fármaco seleccionado de al menos uno de gonadotropina coriónica humana (HCG), seleccionada del grupo que consiste de HCG nativa y HCG recombinante, para usarse en el tratamiento de dolor crónico, en donde el fármaco está adaptado para ser administrable a un paciente a, o equivalente a una dosificación subcutánea diaria de HCG de entre 120 IU/y 170 IU/día.
MX2013012078A 2011-04-15 2012-04-16 Metodo para manejo de dolor cronico y tratamiento usando hcg. MX359672B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161475908P 2011-04-15 2011-04-15
US13/211,101 US8680086B2 (en) 2011-04-15 2011-08-16 Methods for chronic pain management and treatment using HCG
US13/311,250 US20120265129A1 (en) 2011-04-15 2011-12-05 Methods for Chronic Pain Management and Treatment using HCG
PCT/US2012/033828 WO2012142609A1 (en) 2011-04-15 2012-04-16 Methods for chronic pain management and treatment using hcg

Publications (2)

Publication Number Publication Date
MX2013012078A MX2013012078A (es) 2015-08-06
MX359672B true MX359672B (es) 2018-10-05

Family

ID=47006948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012078A MX359672B (es) 2011-04-15 2012-04-16 Metodo para manejo de dolor cronico y tratamiento usando hcg.

Country Status (12)

Country Link
US (3) US20120265129A1 (es)
EP (1) EP2696885B1 (es)
JP (3) JP2014510797A (es)
KR (1) KR102029187B1 (es)
CN (2) CN103596647A (es)
AU (1) AU2012242443C1 (es)
BR (1) BR112013026284B1 (es)
CA (1) CA2864875C (es)
DK (1) DK2696885T3 (es)
MX (1) MX359672B (es)
RU (2) RU2013150024A (es)
WO (1) WO2012142609A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
BR112015008753A2 (pt) 2012-10-18 2017-07-04 Neuralight Hd Llc tratamento de depressão e ptsd
WO2016077565A2 (en) * 2014-11-12 2016-05-19 Neuralight Hd, Llc Methods for chronic pain management and treatment using hcg
US10143625B2 (en) 2015-03-17 2018-12-04 Recon Therapeutics, Inc. Pharmaceutical reconstitution
US20220175701A1 (en) * 2020-12-08 2022-06-09 Therapeutic Solutions International, Inc. Treatment of major depressive disorder and suicidal ideations through stimulation of hippocampal neurogenesis utilizing plant-based approaches

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689222A (en) 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5677275A (en) 1994-08-05 1997-10-14 The United States Of America As Represented By The Department Of Health And Human Services Treatment of cancer with human chorionic gonadotropin
EP0814841B1 (en) 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Hcg liquid formulations
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US6488649B1 (en) 1998-11-24 2002-12-03 Edward M. Lichten Implant device
US6417184B1 (en) * 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
US20020123670A1 (en) * 2000-12-29 2002-09-05 Goetzke Gary A. Chronic pain patient diagnostic system
AR036592A1 (es) * 2001-09-12 2004-09-22 Applied Research Systems Uso de gch en la hiperestimulacion ovarica controlada
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
EP1596881B1 (en) 2003-02-07 2008-12-10 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Use of human chorionic gonadotropin in the treatment of symptoms caused by endometriosis
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
JP2009530234A (ja) 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン
CN1865944A (zh) * 2006-06-15 2006-11-22 福州大学 无创定量hcg检测方法
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG

Also Published As

Publication number Publication date
CA2864875A1 (en) 2012-10-18
EP2696885B1 (en) 2019-11-20
KR20140043731A (ko) 2014-04-10
AU2012242443C1 (en) 2016-06-16
EP2696885A1 (en) 2014-02-19
CN103596647A (zh) 2014-02-19
WO2012142609A1 (en) 2012-10-18
AU2012242443A1 (en) 2013-05-02
JP2019189660A (ja) 2019-10-31
AU2012242443B2 (en) 2015-12-10
RU2017112735A3 (es) 2020-08-03
CA2864875C (en) 2020-08-18
JP2017206500A (ja) 2017-11-24
EP2696885A4 (en) 2014-11-05
JP2014510797A (ja) 2014-05-01
RU2017112735A (ru) 2019-01-25
DK2696885T3 (da) 2020-02-03
RU2013150024A (ru) 2015-05-20
US20150057224A1 (en) 2015-02-26
CN107469072A (zh) 2017-12-15
BR112013026284B1 (pt) 2022-09-20
US8680088B2 (en) 2014-03-25
US20130196914A1 (en) 2013-08-01
US20120265129A1 (en) 2012-10-18
MX2013012078A (es) 2015-08-06
KR102029187B1 (ko) 2019-10-07
JP6571713B2 (ja) 2019-09-04
RU2755938C2 (ru) 2021-09-23
BR112013026284A2 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
MX359672B (es) Metodo para manejo de dolor cronico y tratamiento usando hcg.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
NZ707377A (en) Combination therapy methods for treating proliferative diseases
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
NZ604029A (en) Methods of treating bladder cancer
GB201111485D0 (en) Drug composition and its use in therapy
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
TW200628182A (en) Injection device for administering a medication liquid
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
TW200724189A (en) Method of and system for predicting dose delivery
MX2015004940A (es) Tratamiento de depresion y ptsd.
Fakheri et al. Evaluation of lithium chronic effects on thyroid tissues and its secreted hormones in female rats.
Mikheev et al. A case of beneficial outcome of acute poisoning with potentially lethal doses of paracetamol
EA201491046A1 (ru) Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
UA132469U (uk) Спосіб лікування дефіциту гормону щитовидної залози
UA83721U (ru) Способ стимуляции многоплодия и крупноплодия овцематок
UA54839U (ru) Способ лечения псориаза

Legal Events

Date Code Title Description
FG Grant or registration